Company intelligence / Profile preview

Genelex

Seattle, Washington, United Statesgenelex.jp ↗

Ownership: Private
Development stage: Other

Overview

Genelex was an early leader in clinical pharmacogenetic testing and medication analytics. Its YouScript platform provided actionable genetic insights for healthcare providers to optimize prescribing safety. The company’s solutions were used by clinicians, researchers, CROs, payers, and pharmaceutical companies. It was acquired by Invitae in March 2020. No ongoing clinical trials or new programs post-acquisition.

Therapeutic areas: PsychiatryOther
Modalities: Diagnostic test (pharmacogenetic testing)Software (clinical decision support tool)
Industry: Molecular Diagnostics

Partnerships

Collaborated with healthcare providers/hospitals/CROs; no major pharma partnerships publicly listed.

Beyond the preview

Go deeper on Genelex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genelex.

Explore the full profile